$RNAC SEC Filings

Filed On	Filing
29 Sep 2026	8-K: Regulation FD Disclosure; Other Events Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
13 Aug 2026	SCHEDULE 13G
06 Aug 2026	10-Q
06 Aug 2026	8-K: Results of Operations and Financial Condition
22 Jul 2026	SCHEDULE 13G/A
17 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
09 Jun 2026	144
09 Jun 2026	8-K: Regulation FD Disclosure
02 Jun 2026	144
26 May 2026	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +3 more
06 May 2026	SCHEDULE 13G/A
30 Apr 2026	S-8
30 Apr 2026	10-Q
30 Apr 2026	8-K: Results of Operations and Financial Condition
28 Apr 2026	DEFA14A
28 Apr 2026	Proxy statement: annual meeting on June 12, 2026 CEO pay $4.3M, down 41% · say-on-pay vote
06 Apr 2026	Form 4: Hoge Elizabeth, 10% owner and 1 other Received 758,001 shares by exercise or conversion
06 Apr 2026	Form 4: Kalayoglu Murat, 10% owner Received 758,001 shares by exercise or conversion
02 Apr 2026	SCHEDULE 13D/A
30 Mar 2026	8-K: Departure/Election of Directors or Officers; Compensation

Comments